CoChat
Sign Up
Cited by 30Acute Myeloid Leukemia ResearchMicroRNA in disease regulationImmune cells in cancer

MicroRNAs Associated With a Good Prognosis of Acute Myeloid Leukemia and Their Effect on Macrophage Polarization

Open access
Neaga, Alexandra, Bagacean, Cristina, Tempescul, Adrian, Jimbu, Laura, Mesaros, Oana, Blag, Cristina, Tomuleasa, Ciprian, Bocsan, Corina +2 more·2021·Frontiers in Immunology
DOI 10.3389/fimmu.2020.582915PMC PMC7845488
Open this paper in CoChat — free accountOpen PDF

Abstract

Acute myeloid leukemia (AML) is an aggressive myeloid malignancy with poor outcomes despite very intensive therapeutic approaches. For the majority of patients which are unfit and treated less intensively, the prognosis is even worse. There has been unspectacular progress in outcome improvement over the last decades and the development of new approaches is of tremendous interest. The tumor microenvironment is credited with an important role in supporting cancer growth, including leukemogenesis. Macrophages are part of the tumor microenvironment and their contribution in this setting is increasingly being deciphered, these cells being credited with a tumor supporting role. Data on macrophage role and polarization in leukemia is scarce. MicroRNAs (miRNAs) have a role in the post-transcriptional regulation of gene expression, by impending translation and promoting degradation of messenger RNAs. They are important modulators of cellular pathways, playing major roles in normal hematopoietic differentiation. miRNA expression is significantly correlated with the prognosis of hematopoietic malignancies, including AML. Oncogenic miRNAs correlate with poor prognosis, while tumor suppressor miRNAs, which inhibit the expression of proto-oncogenes, are correlated with a favorable prognosis. miRNAs are proposed as biomarkers for diagnosis and prognosis and are regarded as therapeutic approaches in many cancers, including AML. miRNAs with epigenetic or modulatory activity, as well as with synergistic activity with chemotherapeutic agents, proved to be promising therapeutic targets in experimental, pre-clinical approaches. The clinical availability of emerging compounds with mimicking or suppressor activity provides the opportunity for future therapeutic targeting of miRNAs. The present paper is focusing on miRNAs which, according to current knowledge, favorably impact on AML outcomes, being regarded as tumor suppressors, and reviews their role in macrophage polarization. We are focusing on miRNA expression in the setting of AML, but data on correlations between miRNA expression and macrophage polarization is mostly coming from studies involving normal tissue.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2020.582915

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The appearance of anti-inflammatory cytokines, such as IL-10, IL-4 or IL-13, promotes the M2 phenotype, which is coordinated by the STAT-6 transcription factor.

    “In turn, the appearance of anti-inflammatory cytokines, such as IL-10, IL-4 or IL-13, promotes the M2 phenotype, which is coordinated by the STAT-6 transcription factor [192,193,194].”

    From MicroRNAs as Regulators of Phagocytosis (2022) · cites this paper as [194]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 112

  1. [1]Khanal N Upadhyay Banskota S Bhatt VR Novel treatment paradigms in acute myeloid leukemia. Clin Pharmacol Ther (2020) 108(3): 506–14. 10.1002/cpt.1962 PMC9278561 32572947 · DOI
  2. [2]Pulikkan JA Dengler V Peramangalam PS Peer Zada AA Muller-Tidow C Bohlander SK Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. Blood (2010) 115(9): 1768–78. 10.1182/blood-2009-08-240101 PMC2832809 20029046 · DOI
  3. [3]Pulikkan JA Peramangalam PS Dengler V Ho PA Preudhomme C Meshinchi S C/EBPalpha regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. Blood (2010) 116(25): 5638–49. 10.1182/blood-2010-04-281600 PMC3031410 20889924 · DOI
  4. [4]Katzerke C Madan V Gerloff D Brauer-Hartmann D Hartmann JU Wurm AA Transcription factor C/EBPalpha-induced microRNA-30c inactivates Notch1 during granulopoiesis and is downregulated in acute myeloid leukemia. Blood (2013) 122(14): 2433–42. 10.1182/blood-2012-12-472183 PMC3790511 23974200 · DOI
  5. [5]O’Connell RM Chaudhuri AA Rao DS Baltimore D Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci U S A (2009) 106(17): 7113–8. 10.1073/pnas.0902636106 PMC2678424 19359473 · DOI · Paper page
  6. [6]O’Connell RM Rao DS Chaudhuri AA Baltimore D Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol (2010) 10(2): 111–22. 10.1038/nri2708 20098459 · DOI
  7. [7]Elton TS Selemon H Elton SM Parinandi NL Regulation of the MIR155 host gene in physiological and pathological processes. Gene (2013) 532(1): 1– 12. 10.1016/j.gene.2012.12.009 23246696 · DOI
  8. [8]Marcucci G Maharry KS Metzeler KH Volinia S Wu YZ Mrozek K Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol (2013) 31(17): 2086–93. 10.1200/JCO.2012.45.6228 PMC3731981 23650424 · DOI
  9. [9]Al-Matary YS Botezatu L Opalka B Hones JM Lams RF Thivakaran A Acute myeloid leukemia cells polarize macrophages towards a leukemia supporting state in a Growth factor independence 1 dependent manner. Haematologica (2016) 101(10): 1216–27. 10.3324/haematol.2016.143180 PMC5046651 27390361 · DOI
  10. [10]Merien F A journey with Elie Metchnikoff: from innate cell mechanisms in infectious diseases to quantum biology. Front Public Health (2016) 4: 125. 10.3389/fpubh.2016.00125 27379227 PMC4909730 · DOI
  11. [11]Wynn TA Vannella KM Macrophages in tissue repair, regeneration, and fibrosis. Immunity (2016) 44(3): 450–62. 10.1016/j.immuni.2016.02.015 PMC4794754 26982353 · DOI · Paper page
  12. [13]Zdrenghea MT Makrinioti H Muresan A Johnston SL Stanciu LA The role of macrophage IL-10/innate IFN interplay during virus-induced asthma. Rev Med Virol (2015) 25(1): 33– 49. 10.1002/rmv.1817 25430775 PMC4316183 · DOI
  13. [14]Feketea G Bocsan CI Popescu C Gaman M Stanciu LA Zdrenghea MT A Review of Macrophage MicroRNAs’ Role in Human Asthma. Cells (2019) 8(5): 420. 10.3390/cells8050420 PMC6562863 31071965 · DOI
  14. [17]Murray PJ Macrophage polarization. Annu Rev Physiol (2017) 79: 541–66. 10.1146/annurev-physiol-022516-034339 27813830 · DOI · Paper page
  15. [18]Orecchioni M Ghosheh Y Pramod AB Ley K Macrophage polarization: different gene signatures in M1 (LPS+) vs. classically and M2 (LPS–) vs. alternatively activated macrophages. Front Immunol (2019) 10: 1084. 10.3389/fimmu.2019.01084 31178859 PMC6543837 · DOI · Paper page
  16. [21]Yang X Feng W Wang R Yang F Wang L Chen S Repolarizing heterogeneous leukemia-associated macrophages with more M1 characteristics eliminates their pro-leukemic effects. Oncoimmunology (2018) 7(4): e1412910. 10.1080/2162402X.2017.1412910 29632729 PMC5889280 · DOI
  17. [22]Fayyad-Kazan H Bitar N Najar M Lewalle P Fayyad-Kazan M Badran R Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. J Trans Med (2013) 11(1): 1– 10. 10.1186/1479-5876-11-31 PMC3579719 23391324 · DOI
  18. [23]Squadrito ML Etzrodt M De Palma M Pittet MJ MicroRNA-mediated control of macrophages and its implications for cancer. Trends Immunol (2013) 34(7): 350–9. 10.1016/j.it.2013.02.003 PMC3700601 23498847 · DOI
  19. [25]Cobos Jimenez V Willemsen AM Bradley EJ Baas F van Kampen AH Kootstra NA Next-generation sequencing of microRNAs in primary human polarized macrophages. Genom Data (2014) 2: 181–3. 10.1016/j.gdata.2014.06.019 PMC4535945 26484091 · DOI
  20. [26]Chai ZT Zhu XD Ao JY Wang WQ Gao DM Kong J microRNA-26a suppresses recruitment of macrophages by down-regulating macrophage colony-stimulating factor expression through the PI3K/Akt pathway in hepatocellular carcinoma. J Hematol Oncol (2015) 8: 56. 10.1186/s13045-015-0150-4 26021873 PMC4455972 · DOI
  21. [27]Essandoh K Li Y Huo J Fan GC Mirna-Mediated Macrophage Polarization and its Potential Role in the Regulation of Inflammatory Response. Shock (2016) 46: 122. 10.1097/SHK.0000000000000604 26954942 PMC4949115 · DOI
  22. [28]Veremeyko T Siddiqui S Sotnikov I Yung A Ponomarev ED IL-4/IL-13-dependent and independent expression of miR-124 and its contribution to M2 phenotype of monocytic cells in normal conditions and during allergic inflammation. PLoS One (2013) 8(12): e81774. 10.1371/journal.pone.0081774 24358127 PMC3864800 · DOI · Paper page
  23. [29]Wang X Li Y Dai Y Liu Q Ning S Liu J Sulforaphane improves chemotherapy efficacy by targeting cancer stem cell-like properties via the miR-124/IL-6R/STAT3 axis. Sci Rep (2016) 6: 36796. 10.1038/srep36796 27824145 PMC5099878 · DOI
  24. [30]Schulert GS Fall N Harley JB Shen N Lovell DJ Thornton S Monocyte MicroRNA Expression in Active Systemic Juvenile Idiopathic Arthritis Implicates MicroRNA-125a-5p in Polarized Monocyte Phenotypes. Arthritis Rheumatol (2016) 68(9): 2300–13. 10.1002/art.39694 PMC5001902 27014994 · DOI
  25. [32]Li Y Gao L Luo X Wang L Gao X Wang W Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. Blood (2013) 121(3): 499– 509. 10.1182/blood-2012-07-444729 23223432 · DOI
  26. [33]Eigsti RL Sudan B Wilson ME Graff JW Regulation of activation-associated microRNA accumulation rates during monocyte-to-macrophage differentiation. J Biol Chem (2014) 289(41): 28433–47. 10.1074/jbc.M114.599316 PMC4192495 25148686 · DOI
  27. [34]Ying W Tseng A Chang RC Morin A Brehm T Triff K MicroRNA-223 is a crucial mediator of PPARgamma-regulated alternative macrophage activation. J Clin Invest (2015) 125(11): 4149–59. 10.1172/JCI81656 PMC4639972 26436647 · DOI · Paper page
  28. [35]Ip WKE Hoshi N Shouval DS Snapper S Medzhitov R Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages. Science (2017) 356(6337): 513–9. 10.1126/science.aal3535 PMC6260791 28473584 · DOI
  29. [36]Nishioka C Ikezoe T Pan B Xu K Yokoyama A MicroRNA-9 plays a role in interleukin-10-mediated expression of E-cadherin in acute myelogenous leukemia cells. Cancer Sci (2017) 108(4): 685–95. 10.1111/cas.13170 PMC5406602 28107581 · DOI
  30. [38]Dai CW Bai QW Zhang GS Cao YX Shen JK Pei MF MicroRNA let-7f is down-regulated in patients with refractory acute myeloid leukemia and is involved in chemotherapy resistance of adriamycin-resistant leukemic cells. Leuk Lymphoma (2014) 55(7): 1645–8. 10.3109/10428194.2013.847936 24067109 · DOI
  31. [39]Garzon R Volinia S Liu CG Fernandez-Cymering C Palumbo T Pichiorri F MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood (2008) 111(6): 3183–9. 10.1182/blood-2007-07-098749 PMC2265455 18187662 · DOI
  32. [40]Jiang X Hu C Arnovitz S Bugno J Yu M Zuo Z miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia. Nat Commun (2016) 7: 11452. 10.1038/ncomms11452 27116251 PMC5477496 · DOI
  33. [41]Salvatori B Iosue I Djodji Damas N Mangiavacchi A Chiaretti S Messina M Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2. Genes Cancer (2011) 2(5): 585–92. 10.1177/1947601911416357 PMC3161419 21901171 · DOI
  34. [42]Gong JN Yu J Lin HS Zhang XH Yin XL Xiao Z The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia. Cell Death Differ (2014) 21(1): 100–12. 10.1038/cdd.2013.133 PMC3857615 24076586 · DOI
  35. [43]Liu L Ren W Chen K MiR-34a Promotes Apoptosis and Inhibits Autophagy by Targeting HMGB1 in Acute Myeloid Leukemia Cells. Cell Physiol Biochem (2017) 41(5): 1981–92. 10.1159/000475277 28478444 · DOI
  36. [44]Pelosi A Careccia S Lulli V Romania P Marziali G Testa U miRNA let-7c promotes granulocytic differentiation in acute myeloid leukemia. Oncogene (2013) 32(31): 3648–54. 10.1038/onc.2012.398 PMC7228025 22964640 · DOI
  37. [45]Liu H Pattie P Chandrasekara S Spencer A Dear AE Epigenetic regulation of miRNA-124 and multiple downstream targets is associated with treatment response in myeloid malignancies. Oncol Lett (2016) 12(3): 2175–80. 10.3892/ol.2016.4912 PMC4998575 27602159 · DOI
  38. [46]Spinello I Quaranta MT Paolillo R Pelosi E Cerio AM Saulle E Differential hypoxic regulation of the microRNA-146a/CXCR4 pathway in normal and leukemic monocytic cells: impact on response to chemotherapy. Haematologica (2015) 100(9): 1160–71. 10.3324/haematol.2014.120295 PMC4800689 26045293 · DOI
  39. [47]Gao XN Lin J Li YH Gao L Wang XR Wang W MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia. Oncogene (2011) 30(31): 3416–28. 10.1038/onc.2011.62 21399664 · DOI
  40. [48]Xiao Y Su C Deng T miR-223 decreases cell proliferation and enhances cell apoptosis in acute myeloid leukemia via targeting FBXW7. Oncol Lett (2016) 12(5): 3531–6. 10.3892/ol.2016.5115 PMC5103979 27900032 · DOI
  41. [49]Rowe RG Wang LD Coma S Han A Mathieu R Pearson DS Developmental regulation of myeloerythroid progenitor function by the Lin28b-let-7-Hmga2 axis. J Exp Med (2016) 213(8): 1497–512. 10.1084/jem.20151912 PMC4986532 27401346 · DOI
  42. [50]Zhou J Chan ZL Bi C Lu X Chong PS Chooi JY LIN28B Activation by PRL-3 Promotes Leukemogenesis and a Stem Cell-like Transcriptional Program in AML. Mol Cancer Res (2017) 15(3): 294– 303. 10.1158/1541-7786.MCR-16-0275-T 28011885 · DOI
  43. [52]Lu L McCurdy S Huang S Zhu X Peplowska K Tiirikainen M Time Series miRNA-mRNA integrated analysis reveals critical miRNAs and targets in macrophage polarization. Sci Rep (2016) 6: 37446. 10.1038/srep37446 27981970 PMC5159803 · DOI
  44. [53]Zhang W Liu H Liu W Liu Y Xu J Polycomb-mediated loss of microRNA let-7c determines inflammatory macrophage polarization via PAK1-dependent NF-kappaB pathway. Cell Death Differ (2015) 22(2): 287–97. 10.1038/cdd.2014.142 PMC4291490 25215948 · DOI
  45. [54]Kumar M Sahu SK Kumar R Subuddhi A Maji RK Jana K MicroRNA let-7 modulates the immune response to Mycobacterium tuberculosis infection via control of A20, an inhibitor of the NF-kappaB pathway. Cell Host Microbe (2015) 17(3): 345–56. 10.1016/j.chom.2015.01.007 25683052 · DOI
  46. [55]Gao SM Xing CY Chen CQ Lin SS Dong PH Yu FJ miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level. J Exp Clin Cancer Res (2011) 30: 110. 10.1186/1756-9966-30-110 22133358 PMC3245444 · DOI
  47. [56]Abraham M Klein S Bulvik B Wald H Weiss ID Olam D The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by down-regulating ERK BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression. Leukemia (2017) 31: 2336–46. 10.1038/leu.2017.82 28280274 · DOI
  48. [57]Kim KT Carroll AP Mashkani B Cairns MJ Small D Scott RJ MicroRNA-16 is down-regulated in mutated FLT3 expressing murine myeloid FDC-P1 cells and interacts with Pim-1. PLoS One (2012) 7(9): e44546. 10.1371/journal.pone.0044546 22970245 PMC3435263 · DOI
  49. [58]Borthakur G Nagler A Ofran Y Rowe JM Altman JK Frankfurt O BL-8040, a peptidic CXCR4 antagonist, induces leukemia cell death and specific leukemia cell mobilization in relapsed/refractory acute myeloid leukemia patients in an ongoing phase IIa clinical trial. Am Soc Hematol Washington DC (2014) 124: 950. 10.1182/blood.V124.21.950.950 · DOI
  50. [59]Abraham M Pereg Y Bulvik B Klein S Mishalian I Wald H Single dose of the CXCR4 antagonist BL-8040 induces rapid mobilization for the collection of human CD34+ cells in healthy volunteers. Clin Cancer Res (2017) 23(22): 6790–801. 10.1158/1078-0432.CCR-16-2919 28835380 · DOI
  51. [60]Cho B-S Zeng Z Mu H Wang Z Konoplev S McQueen T Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood (2015) 126(2): 222–32. 10.1182/blood-2015-02-628677 PMC4497963 26031918 · DOI
  52. [61]van Zandwijk N Pavlakis N Kao SC Linton A Boyer MJ Clarke S Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. Lancet Oncol (2017) 18(10): 1386–96. 10.1016/S1470-2045(17)30621-6 28870611 · DOI
  53. [63]Jinlong S Lin F Yonghui L Li Y Weidong W Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemia. PLoS One (2015) 10(2): e0118099. 10.1371/journal.pone.0118099 25646775 PMC4315415 · DOI
  54. [64]Wang Y Li Z He C Wang D Yuan X Chen J MicroRNAs expression signatures are associated with lineage and survival in acute leukemias. Blood Cells Mol Dis (2010) 44(3): 191–7. 10.1016/j.bcmd.2009.12.010 PMC2829339 20110180 · DOI
  55. [65]Cheng J Guo S Chen S Mastriano SJ Liu C D’Alessio AC An extensive network of TET2-targeting MicroRNAs regulates malignant hematopoiesis. Cell Rep (2013) 5(2): 471–81. 10.1016/j.celrep.2013.08.050 PMC3834864 24120864 · DOI
  56. [66]Kota J Chivukula RR O’Donnell KA Wentzel EA Montgomery CL Hwang HW Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 137(6): 1005–17. 10.1016/j.cell.2009.04.021 PMC2722880 19524505 · DOI
  57. [67]Salvatori B Iosue I Mangiavacchi A Loddo G Padula F Chiaretti S The microRNA-26a target E2F7 sustains cell proliferation and inhibits monocytic differentiation of acute myeloid leukemia cells. Cell Death Dis (2012) 3: e413. 10.1038/cddis.2012.151 23096114 PMC3481138 · DOI
  58. [68]Jiang W Min J Sui X Qian Y Liu Y Liu Z MicroRNA-26a-5p and microRNA-23b-3p up-regulate peroxiredoxin III in acute myeloid leukemia. Leuk Lymphoma (2015) 56(2): 460–71. 10.3109/10428194.2014.924115 PMC4364273 24828865 · DOI
  59. [69]Ngankeu A Ranganathan P Havelange V Nicolet D Volinia S Powell BL Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget (2018) 9(4): 4354. 10.18632/oncotarget.23150 29435107 PMC5796978 · DOI
  60. [70]Garzon R Heaphy CE Havelange V Fabbri M Volinia S Tsao T MicroRNA 29b functions in acute myeloid leukemia. Blood (2009) 114(26): 5331–41. 10.1182/blood-2009-03-211938 PMC2796138 19850741 · DOI
  61. [71]Xiong Y Li Z Ji M Tan AC Bemis J Tse JV MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML. Br J Haematol (2011) 153(6): 753–7. 10.1111/j.1365-2141.2011.08662.x PMC3896048 21496004 · DOI
  62. [72]Wang F Wang XS Yang GH Zhai PF Xiao Z Xia LY miR-29a and miR-142-3p downregulation and diagnostic implication in human acute myeloid leukemia. Mol Biol Rep (2012) 39(3): 2713–22. 10.1007/s11033-011-1026-5 21678057 · DOI
  63. [73]Xu L Xu Y Jing Z Wang X Zha X Zeng C Altered expression pattern of miR-29a, miR-29b and the target genes in myeloid leukemia. Exp Hematol Oncol (2014) 3: 17. 10.1186/2162-3619-3-17 25006537 PMC4086441 · DOI
  64. [74]Mott JL Kurita S Cazanave SC Bronk SF Werneburg NW Fernandez-Zapico ME Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB. J Cell Biochem (2010) 110(5): 1155–64. 10.1002/jcb.22630 PMC2922950 20564213 · DOI · Paper page
  65. [75]Eyholzer M Schmid S Wilkens L Mueller BU Pabst T The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML. Br J Cancer (2010) 103(2): 275–84. 10.1038/sj.bjc.6605751 PMC2906742 20628397 · DOI
  66. [76]Garzon R Liu S Fabbri M Liu Z Heaphy CE Callegari E MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood (2009) 113(25): 6411–8. 10.1182/blood-2008-07-170589 PMC2710934 19211935 · DOI
  67. [77]Amodio N Rossi M Raimondi L Pitari MR Botta C Tagliaferri P miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. Oncotarget (2015) 6(15): 12837–61. 10.18632/oncotarget.3805 PMC4536984 25968566 · DOI
  68. [78]Bhise NS Chauhan L Shin M Cao X Pounds S Lamba V MicroRNA-mRNA Pairs Associated with Outcome in AML: From In Vitro Cell-Based Studies to AML Patients. Front Pharmacol (2015) 6: 324. 10.3389/fphar.2015.00324 26858643 PMC4729948 · DOI
  69. [79]Amodio N Di Martino MT Foresta U Leone E Lionetti M Leotta M miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis (2012) 3: e436. 10.1038/cddis.2012.175 23190608 PMC3542610 · DOI
  70. [80]Shah NM Zaitseva L Bowles KM MacEwan DJ Rushworth SA NRF2-driven miR-125B1 and miR-29B1 transcriptional regulation controls a novel anti-apoptotic miRNA regulatory network for AML survival. Cell Death Differ (2015) 22(4): 654–64. 10.1038/cdd.2014.152 PMC4356334 25323587 · DOI
  71. [81]Liu S Wu LC Pang J Santhanam R Schwind S Wu YZ Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell (2010) 17(4): 333–47. 10.1016/j.ccr.2010.03.008 PMC2917066 20385359 · DOI
  72. [82]Mims A Walker AR Huang X Sun J Wang H Santhanam R Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia (2013) 27(4): 871–8. 10.1038/leu.2012.342 PMC3764604 23178755 · DOI
  73. [83]Amodio N Bellizzi D Leotta M Raimondi L Biamonte L D’Aquila P miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle (2013) 12(23): 3650–62. 10.4161/cc.26585 PMC3903716 24091729 · DOI
  74. [84]Stapnes C Ryningen A Hatfield K Oyan AM Eide GE Corbascio M Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors. Int J Oncol (2007) 31(6): 1529–38. 10.3892/ijo.31.6.1529 17982680 · DOI
  75. [85]Blum W Garzon R Klisovic RB Schwind S Walker A Geyer S Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A (2010) 107(16): 7473–8. 10.1073/pnas.1002650107 PMC2867720 20368434 · DOI
  76. [86]Blum W Schwind S Tarighat SS Geyer S Eisfeld AK Whitman S Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood (2012) 119(25): 6025–31. 10.1182/blood-2012-03-413898 PMC3383015 22566605 · DOI
  77. [87]Huang X Schwind S Yu B Santhanam R Wang H Hoellerbauer P Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res (2013) 19(9): 2355–67. 10.1158/1078-0432.CCR-12-3191 PMC3644023 23493348 · DOI
  78. [88]Pigazzi M Manara E Bresolin S Tregnago C Beghin A Baron E MicroRNA-34b promoter hypermethylation induces CREB overexpression and contributes to myeloid transformation. Haematologica (2013) 98(4): 602–10. 10.3324/haematol.2012.070664 PMC3659992 23100280 · DOI
  79. [89]Zhao J Lammers P Torrance CJ Bader AG TP53-independent function of miR-34a via HDAC1 and p21(CIP1/WAF1.). Mol Ther (2013) 21(9): 1678–86. 10.1038/mt.2013.148 PMC3776635 23836017 · DOI
  80. [91]Di Martino MT Campani V Misso G Gallo Cantafio ME Gulla A Foresta U In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. PLoS One (2014) 9(2): e90005. 10.1371/journal.pone.0090005 24587182 PMC3937395 · DOI
  81. [92]Wang X Li J Dong K Lin F Long M Ouyang Y Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signall (2015) 27(3): 443–52. 10.1016/j.cellsig.2014.12.003 25499621 · DOI
  82. [94]Wang S Wang T Li MZ Cheng XL Li XL Expression of microRNA miR-34a inhibits leukemia stem cells and its metastasis. Eur Rev Med Pharmacol Sci (2016) 20(13): 2878–83. 27424989
  83. [95]Yang DQ Zhou JD Wang YX Deng ZQ Yang J Yao DM Low miR-34c expression is associated with poor outcome in de novo acute myeloid leukemia. Int J Lab Hematol (2017) 39(1): 42– 50. 10.1111/ijlh.12566 27577964 · DOI
  84. [96]Peng D Wang H Li L Ma X Chen Y Zhou H miR-34c-5p promotes eradication of acute myeloid leukemia stem cells by inducing senescence through selective RAB27B targeting to inhibit exosome shedding. Leukemia (2018) 32(5): 1180–8. 10.1038/s41375-018-0015-2 29479064 · DOI
  85. [97]Bader AG miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet (2012) 3: 120. 10.3389/fgene.2012.00120 22783274 PMC3387671 · DOI
  86. [99]Gambari R Brognara E Spandidos DA Fabbri E Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Nuew trends in the development of miRNA therapeutic strategies in oncology (Review). Int J Oncol (2016) 49: 5– 32. 10.3892/ijo.2016.3503 27175518 PMC4902075 · DOI
  87. [100]Wong KY So CC Loong F Chung LP Lam WW Liang R Epigenetic inactivation of the miR-124-1 in haematological malignancies. PLoS One (2011) 6(4): e19027. 10.1371/journal.pone.0019027 21544199 PMC3081325 · DOI
  88. [101]Chen XX Lin J Qian J Qian W Yang J Ma JC Dysregulation of miR-124-1 predicts favorable prognosis in acute myeloid leukemia. Clin Biochem (2014) 47(1-2): 63–6. 10.1016/j.clinbiochem.2013.09.020 24135052 · DOI
  89. [102]Marcucci G Mrózek K Radmacher MD Garzon R Bloomfield CD The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood J Am Soc Hematol (2011) 117(4): 1121–9. 10.1182/blood-2010-09-191312 PMC3056468 21045193 · DOI
  90. [103]Ganan-Gomez I Wei Y Yang H Pierce S Bueso-Ramos C Calin G Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-κB activation and enhances erythroid differentiation arrest. PLoS One (2014) 9(4): e93404. 10.1371/journal.pone.0093404 24690917 PMC3972113 · DOI
  91. [104]Yang M Tang X Wang Z Wu X Tang D Wang D miR-125 inhibits colorectal cancer proliferation and invasion by targeting TAZ. Biosci Rep (2019) 39(12): 1– 10. 10.1042/BSR20190193 PMC6911154 31782506 · DOI
  92. [105]Czimmerer Z Varga T Kiss M Vazquez CO Doan-Xuan QM Ruckerl D The IL-4/STAT6 signaling axis establishes a conserved microRNA signature in human and mouse macrophages regulating cell survival via miR-342-3p. Genome Med (2016) 8(1): 63. 10.1186/s13073-016-0315-y 27245778 PMC4886428 · DOI
  93. [106]Kim JK Noh JH Jung KH Eun JW Bae HJ Kim MG Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology (2013) 57(3): 1055–67. 10.1002/hep.26101 23079745 · DOI
  94. [107]Ufkin ML Peterson S Yang X Driscoll H Duarte C Sathyanarayana P miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia. Leuk Res (2014) 38(3): 402–10. 10.1016/j.leukres.2013.12.021 PMC4117580 24484870 · DOI
  95. [108]Taganov KD Boldin MP Chang KJ Baltimore D NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A (2006) 103(33): 12481–6. 10.1073/pnas.0605298103 PMC1567904 16885212 · DOI · Paper page
  96. [109]So AY Zhao JL Baltimore D The Yin and Yang of microRNAs: leukemia and immunity. Immunol Rev (2013) 253(1): 129–45. 10.1111/imr.12043 PMC3620843 23550643 · DOI
  97. [110]Curtale G Mirolo M Renzi TA Rossato M Bazzoni F Locati M Negative regulation of Toll-like receptor 4 signaling by IL-10-dependent microRNA-146b. Proc Natl Acad Sci U S A (2013) 110(28): 11499–504. 10.1073/pnas.1219852110 PMC3710884 23798430 · DOI
  98. [111]Havelange V Stauffer N Heaphy CC Volinia S Andreeff M Marcucci G Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling. Cancer (2011) 117(20): 4696–706. 10.1002/cncr.26096 PMC3154970 21455993 · DOI
  99. [112]Croasdell A Sime PJ Phipps RP Resolvin D2 decreases TLR4 expression to mediate resolution in human monocytes. FASEB J (2016) 30(9): 3181–93. 10.1096/fj.201600375R PMC5001508 27256622 · DOI
  100. [113]Spinello I Quaranta MT Riccioni R Riti V Pasquini L Boe A MicroRNA-146a and AMD3100, two ways to control CXCR4 expression in acute myeloid leukemias. Blood Cancer J (2011) 1(6): e26. 10.1038/bcj.2011.24 22829170 PMC3255264 · DOI
  101. [114]Magilnick N Reyes EY Wang W-L Vonderfecht SL Gohda J Inoue J-i miR-146a–Traf6 regulatory axis controls autoimmunity and myelopoiesis, but is dispensable for hematopoietic stem cell homeostasis and tumor suppression. Proc Natl Acad Sci (2017) 114(34): E7140–E9. 10.1073/pnas.1706833114 PMC5576818 28784800 · DOI
  102. [115]Fang J Barker B Bolanos L Liu X Jerez A Makishima H Myeloid malignancies with chromosome 5q deletions acquire a dependency on an intrachromosomal NF-kappaB gene network. Cell Rep (2014) 8(5): 1328–38. 10.1016/j.celrep.2014.07.062 PMC4237069 25199827 · DOI
  103. [116]Starczynowski DT Kuchenbauer F Argiropoulos B Sung S Morin R Muranyi A Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med (2010) 16(1): 49– 58. 10.1038/nm.2054 19898489 · DOI
  104. [117]Varney ME Niederkorn M Konno H Matsumura T Gohda J Yoshida N Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling. J Exp Med (2015) 212(11): 1967–85. 10.1084/jem.20141898 PMC4612089 26458771 · DOI
  105. [118]Fu L Fu H Tian L Xu K Hu K Wang J High expression of RUNX1 is associated with poorer outcomes in cytogenetically normal acute myeloid leukemia. Oncotarget (2016) 7(13): 15828–39. 10.18632/oncotarget.7489 PMC4941280 26910834 · DOI
  106. [119]Bhayadia R Krowiorz K Haetscher N Jammal R Emmrich S Obulkasim A Endogenous tumor suppressor microRNA-193b: therapeutic and prognostic value in acute myeloid leukemia. J Clin Oncol (2018) 36(10): 1007–16. 10.1200/JCO.2017.75.2204 29432078 · DOI
  107. [120]Liu Y Cheng Z Pang Y Cui L Qian T Quan L Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia. J Hematol Oncol (2019) 12(1): 51. 10.1186/s13045-019-0734-5 31126316 PMC6534901 · DOI
  108. [121]Gentner B Pochert N Rouhi A Boccalatte F Plati T Berg T MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia. Exp Hematol (2015) 43(10): 858– 68.e7. 10.1016/j.exphem.2015.05.018 26163797 PMC4860732 · DOI
  109. [122]Garzon R Pichiorri F Palumbo T Visentini M Aqeilan R Cimmino A MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene (2007) 26(28): 4148–57. 10.1038/sj.onc.1210186 17260024 · DOI
  110. [123]Brauer-Hartmann D Hartmann JU Wurm AA Gerloff D Katzerke C Verga Falzacappa MV PML/RARalpha-Regulated miR-181a/b Cluster Targets the Tumor Suppressor RASSF1A in Acute Promyelocytic Leukemia. Cancer Res (2015) 75(16): 3411–24. 10.1158/0008-5472.CAN-14-3521 PMC4537849 26041820 · DOI
  111. [124]Li T Morgan MJ Choksi S Zhang Y Kim Y-S Liu Z-g MicroRNAs modulate the noncanonical transcription factor NF-[kappa]B pathway by regulating expression of the kinase IKK[alpha] during macrophage differentiation. Nat Immunol (2010) 11(9): 799– 805. 10.1038/ni.1918 20711193 PMC2926307 · DOI
  112. [125]Fazi F Racanicchi S Zardo G Starnes LM Mancini M Travaglini L Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. Cancer Cell (2007) 12(5): 457–66. 10.1016/j.ccr.2007.09.020 17996649 · DOI

Cited by

Sorted by citations

Authors
Neaga, A., Bagacean, C., Tempescul, A., Jimbu, L., Mesaros, O., Blag, C., Tomuleasa, C., Bocsan, C., Gaman, M., & Zdrenghea, M.
Affiliations
  • Iuliu Hațieganu University of Medicine and Pharmacy (RO)
  • Inserm (FR)
Corresponding author
Zdrenghea, Mihnea
ORCID
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2021-01-15
Volume
11
Pages
582915-582915
ISSN
1664-3224 (ISSN-L)
DOI
10.3389/fimmu.2020.582915
PMC
PMC7845488
OpenAlex
W3124259884
Cited by
30
References
13
Citations by year
2026: 4 · 2025: 4 · 2024: 6 · 2023: 7 · 2022: 7 · 2021: 2
FWCI
0.96
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords
acute myeloid leukemia, microRNA, macrophage polarization, tumor microenvironment, tumor suppressor microRNA, prognosis, biomarkers, miRNA-based therapy
MeSH terms
Animals, Cell Differentiation, Humans, Macrophages, Prognosis, Leukemia, Myeloid, Acute, Gene Expression Regulation, Neoplastic, Cytokines, Th1 Cells, Th2 Cells, MicroRNAs, Epigenesis, Genetic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review